Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
TRVN 
Trevena Inc (TRVN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: TRVN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -15.62% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.10M USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) 1508 | Beta 1.04 | 52 Weeks Range 1.13 - 11.24 | Updated Date 03/31/2025 |
52 Weeks Range 1.13 - 11.24 | Updated Date 03/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -47.81 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-03-31 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1970.67% |
Management Effectiveness
Return on Assets (TTM) -62.39% | Return on Equity (TTM) -1014.58% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 25157980 | Price to Sales(TTM) 2.02 |
Enterprise Value 25157980 | Price to Sales(TTM) 2.02 | ||
Enterprise Value to Revenue 46.08 | Enterprise Value to EBITDA 0.21 | Shares Outstanding 863788 | Shares Floating 812799 |
Shares Outstanding 863788 | Shares Floating 812799 | ||
Percent Insiders 0.48 | Percent Institutions 9.99 |
Analyst Ratings
Rating 3 | Target Price 5 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Trevena Inc
Company Overview
History and Background
Trevena Inc. is a biopharmaceutical company focused on the discovery and development of novel therapies based on G protein-coupled receptors (GPCRs). Founded in 2007, Trevena has focused on developing selective receptor modulators (SAMs) for acute and chronic pain, and other central nervous system disorders. Milestones include the FDA approval of OLINVYK and subsequent challenges scaling sales.
Core Business Areas
- Pain Management: Trevena focuses on developing and commercializing pain management therapies utilizing its SAM technology. This includes intravenous and oral formulations.
Leadership and Structure
Trevena's leadership includes a CEO, CFO, CSO, and other key executives. The organizational structure is typical of a biopharmaceutical company, with departments focused on research, development, clinical trials, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- OLINVYK (oliceridine): OLINVYK is an intravenous opioid analgesic approved for the management of acute moderate to severe pain. Challenges launching product. Competitors include generic IV opioids like morphine and fentanyl, as well as other branded pain medications.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated. The pain management market is large but faces challenges related to opioid abuse and the search for non-addictive alternatives.
Positioning
Trevena aims to carve a niche in the pain management market by developing more selective and potentially safer opioid analgesics. Its competitive advantage is the SAM technology.
Total Addressable Market (TAM)
The global pain management market is estimated to be in the billions of dollars. Trevena's TAM is a subset of this, focusing on acute pain. Trevena's positioning depends on differentiating its products by showing improvements to efficacy and reduced side effects.
Upturn SWOT Analysis
Strengths
- SAM Technology Platform
- FDA Approved Product (OLINVYK)
- Experienced Management Team
Weaknesses
- Limited Commercial Infrastructure
- Reliance on Single Product
- History of net losses
- High debt levels
Opportunities
- Expanding OLINVYK into New Indications
- Partnering with Larger Pharmaceutical Companies
- Developing Novel SAMs for Other CNS Disorders
Threats
- Competition from Existing Opioid Analgesics
- Regulatory Hurdles
- Generic competition
- Negative publicity surrounding opioids
- Difficulty raising capital
Competitors and Market Share
Key Competitors
- JNJ
- PFE
- ABBV
- TEVA
Competitive Landscape
Trevena faces intense competition from larger pharmaceutical companies with established pain management products. Trevena's advantage is its SAM technology and the potential for safer and more effective pain relief.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been dependent on clinical trial success and approval of Olinvyk. Growth has been slow given revenue challenges with Olinvyk.
Future Projections: Future projections depend on the success of commercializing OLINVYK and developing new products. Analyst estimates vary, and can be found on financial websites.
Recent Initiatives: Recent initiatives include efforts to increase awareness and adoption of OLINVYK and seek out strategic partnerships.
Summary
Trevena is a biopharmaceutical company with innovative technology but faces financial challenges and competition. Its key product, OLINVYK, has the potential for growth, but commercial success is crucial. The company needs to manage its debt and expand its pipeline for long-term sustainability. The company's future depends on the success of Olinvyk and the ability to raise capital to keep operating. They need to watch their cash burn and potential dilution.
Similar Companies
- JNJ
- PFE
- ABBV
- TEVA
Sources and Disclaimers
Data Sources:
- Trevena Inc. SEC Filings
- Company Press Releases
- Analyst Reports
- Financial News Websites
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Trevena Inc
Exchange NASDAQ | Headquaters Chesterbrook, PA, United States | ||
IPO Launch date 2014-01-31 | President, CEO & Chairman Ms. Carrie L. Bourdow | ||
Sector Healthcare | Industry Biotechnology | Full time employees 23 | Website https://www.trevena.com |
Full time employees 23 | Website https://www.trevena.com | ||
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.